To view or add a comment, sign in Glucagon-Like Peptide-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome: Integrated Clinical Benefits Cardiovascular-kidney-metabolic (CKM) syndrome reflects the convergence of cardiovascular disease, chronic kidney disease, obesity, and diabetes, conditions that frequently coexist and amplify long-term morbidity and mortality
Since IR governs the pathogenesis of NAFLD, the possible role of PIO in this setting gained special interest during the last two decades
The SUSTAIN trials demonstrated that Ozempic 2 mg reduced A1C by approximately 1.8% from baseline meeting superiority endpoints across all tested populations
However, a small amount of sunlight may still be needed to fully activate the melanin that MT-II stimulates, albeit much less than required by natural tanning
Research Applications: Primarily studied for fat metabolism, particularly visceral fat reduction, and increasingly for its potential neurological effects and cardiovascular benefits